NASDAQ:MASI

Masimo Stock Forecast, Price & News

$245.74
+1.65 (+0.68 %)
(As of 04/16/2021 12:00 AM ET)
Add
Compare
Today's Range
$241.33
Now: $245.74
$246.50
50-Day Range
$220.31
MA: $233.41
$256.08
52-Week Range
$194.30
Now: $245.74
$284.86
Volume266,825 shs
Average Volume329,233 shs
Market Capitalization$13.58 billion
P/E Ratio63.83
Dividend YieldN/A
Beta0.87
Masimo Corporation develops, manufactures, and markets noninvasive monitoring technologies and hospital automation solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry. It also provides Masimo rainbow SET platform that includes rainbow SET Pulse CO-Oximetry products that noninvasively monitor hemoglobin species, including oxygen saturation, pulse rate, perfusion index, pleth variability index, and respiration rate from the pleth; noninvasively monitor hemoglobin concentration, and carboxyhemoglobin and methemoglobin; monitor arterial oxygen saturation and acoustic respiration rate; and calculates oxygen content and oxygen reserve index. The company offers SedLine brain function monitoring technology to measure the brain's electrical activity by detecting EEG signals; capnography and gas monitoring products comprising external plug-in-and-measure capnography and gas analyzers, integrated modules, handheld capnograph and capnometer devices, and capnography sampling lines; O3 regional oximetry for tissue oxygen saturation measurement; and hemodynamic monitoring solutions. Its Masimo Hospital Automation platform includes Patient SafetyNet, Patient SafetyNet surveillance, Kite, UniView, Replica, UniView : 60, and MyView. The company offers coronavirus-2019 response and telehealth solutions; connectivity devices; and nasal high flow ventilation and neuromodulation solutions. The company provides its products through direct sales force, distributors, and original equipment manufacturers partners to hospitals, emergency medical service and home care providers, physician offices, long term care facilities, veterinarians, and consumers; and non-medical/consumer products through e-commerce site, masimopersonalhealth.com. The company was incorporated in 1989 and is headquartered in Irvine, California.
Masimo logo

Industry, Sector and Symbol

Industry Electromedical equipment
Sub-IndustryHealth Care Equipment
SectorMedical
Current SymbolNASDAQ:MASI
CUSIP57479510
Phone949-297-7000
Employees2,000
Year Founded1989

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$937.84 million
Cash Flow$3.46 per share
Book Value$21.90 per share

Profitability

Net Income$196.22 million

Miscellaneous

Market Cap$13.58 billion
Next Earnings Date4/27/2021 (Confirmed)
OptionableOptionable

Headlines

Masimo Co. (NASDAQ:MASI) CFO Sells $498,793.00 in Stock
April 12, 2021 |  americanbankingnews.com
Comparing Masimo (NASDAQ:MASI) and Outset Medical (NASDAQ:OM)
March 30, 2021 |  americanbankingnews.com
Ecolab (ECL) Unveils Its Enhanced Smart Water Navigator
March 29, 2021 |  finance.yahoo.com
Piper Sandler Trims Masimo (NASDAQ:MASI) Target Price to $295.00
March 24, 2021 |  americanbankingnews.com
See More Headlines

MarketRank

Overall MarketRank

1.57 out of 5 stars

Medical Sector

411th out of 2,021 stocks

Electromedical Equipment Industry

9th out of 61 stocks

Analyst Opinion: 2.4Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.3 5 -4 -3 -2 -1 -
$245.74
+1.65 (+0.68 %)
(As of 04/16/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive MASI News and Ratings via Email

Sign-up to receive the latest news and ratings for MASI and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Masimo (NASDAQ:MASI) Frequently Asked Questions

Is Masimo a buy right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Masimo in the last year. There are currently 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Masimo stock.
View analyst ratings for Masimo
or view top-rated stocks.

What stocks does MarketBeat like better than Masimo?

Wall Street analysts have given Masimo a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Masimo wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Masimo's next earnings date?

Masimo is scheduled to release its next quarterly earnings announcement on Tuesday, April 27th 2021.
View our earnings forecast for Masimo
.

How can I listen to Masimo's earnings call?

Masimo will be holding an earnings conference call on Tuesday, April 27th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Masimo's earnings last quarter?

Masimo Co. (NASDAQ:MASI) released its quarterly earnings data on Monday, February, 22nd. The medical equipment provider reported $0.98 earnings per share for the quarter, beating the consensus estimate of $0.86 by $0.12. The medical equipment provider earned $295.10 million during the quarter, compared to analyst estimates of $287.45 million. Masimo had a net margin of 20.30% and a trailing twelve-month return on equity of 15.75%. Masimo's revenue for the quarter was up 19.2% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.91 earnings per share.
View Masimo's earnings history
.

How has Masimo's stock price been impacted by COVID-19 (Coronavirus)?

Masimo's stock was trading at $182.64 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, MASI stock has increased by 34.5% and is now trading at $245.74.
View which stocks have been most impacted by COVID-19
.

What guidance has Masimo issued on next quarter's earnings?

Masimo updated its FY21 earnings guidance on Tuesday, February, 23rd. The company provided EPS guidance of $3.80 for the period, compared to the Thomson Reuters consensus estimate of $3.77. The company issued revenue guidance of $1.2 billion, compared to the consensus revenue estimate of $1.18 billion.

What price target have analysts set for MASI?

7 equities research analysts have issued 12-month target prices for Masimo's stock. Their forecasts range from $245.00 to $295.00. On average, they expect Masimo's share price to reach $272.20 in the next year. This suggests a possible upside of 10.8% from the stock's current price.
View analysts' price targets for Masimo
or view top-rated stocks among Wall Street analysts.

Who are Masimo's key executives?

Masimo's management team includes the following people:
  • Mr. Joseph E. Kiani, Founder, CEO & Chairman (Age 56, Pay $3M) (LinkedIn Profile)
  • Mr. Micah Young, Exec. VP of Fin. & CFO (Age 42, Pay $713.37k) (LinkedIn Profile)
  • Mr. Bilal Muhsin, Chief Operating Officer (Age 40, Pay $892.51k)
  • Dr. Steven J. Barker, Chairman of Scientific Advisory Board, Chief Science Officer & Director (Age 76, Pay $190k)
  • Mr. Thomas Samuel McClenahan, Exec. VP, Gen. Counsel & Corp. Sec. (Age 48, Pay $718.05k) (LinkedIn Profile)
  • Mr. Anand Sampath, Exec. VP of Operations & Clinical Research (Age 55, Pay $774.84k) (LinkedIn Profile)
  • Mr. J. Todd Koning, Sr. VP & Chief Accounting Officer (Age 49)
  • Mr. Yongsam Lee, Exec. VP & Chief Information Officer (Age 56)
  • Mr. Eli Kammerman, VP of Bus. Devel. & Investor Relations
  • Mr. Jon Coleman, Pres of Worldwide Sales, Professional Services & Medical Affairs (Age 57) (LinkedIn Profile)

What is Joe E. Kiani's approval rating as Masimo's CEO?

136 employees have rated Masimo CEO Joe E. Kiani on Glassdoor.com. Joe E. Kiani has an approval rating of 90% among Masimo's employees.

Who are some of Masimo's key competitors?

What other stocks do shareholders of Masimo own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Masimo investors own include NVIDIA (NVDA), Netflix (NFLX), Shopify (SHOP), Okta (OKTA), PayPal (PYPL), Alibaba Group (BABA), Mastercard (MA), The Trade Desk (TTD), The Walt Disney (DIS) and Twilio (TWLO).

What is Masimo's stock symbol?

Masimo trades on the NASDAQ under the ticker symbol "MASI."

Who are Masimo's major shareholders?

Masimo's stock is owned by a number of institutional and retail investors. Top institutional investors include Retirement Systems of Alabama (0.26%), Scout Investments Inc. (0.13%), State of Alaska Department of Revenue (0.07%), Autus Asset Management LLC (0.03%), Royal London Asset Management Ltd. (0.03%) and Louisiana State Employees Retirement System (0.02%). Company insiders that own Masimo stock include Adam Mikkelson, Anand Sampath, Bilal Muhsin, Craig B Reynolds, H Michael Cohen, Joe E Kiani, Jon Coleman, Micah W Young, Ramshorst David J Van, Sanford Fitch, Steven Barker, Thomas Samuel Mcclenahan and Yongsam Lee.
View institutional ownership trends for Masimo
.

Which major investors are selling Masimo stock?

MASI stock was sold by a variety of institutional investors in the last quarter, including EFG Asset Management Americas Corp., State of Alaska Department of Revenue, and First Citizens Bank & Trust Co.. Company insiders that have sold Masimo company stock in the last year include Adam Mikkelson, Anand Sampath, Bilal Muhsin, Craig B Reynolds, H Michael Cohen, Joe E Kiani, Jon Coleman, Micah W Young, and Thomas Samuel Mcclenahan.
View insider buying and selling activity for Masimo
or view top insider-selling stocks.

Which major investors are buying Masimo stock?

MASI stock was purchased by a variety of institutional investors in the last quarter, including Scout Investments Inc., Retirement Systems of Alabama, Autus Asset Management LLC, Royal London Asset Management Ltd., Louisiana State Employees Retirement System, Pacer Advisors Inc., and Crossmark Global Holdings Inc..
View insider buying and selling activity for Masimo
or or view top insider-buying stocks.

How do I buy shares of Masimo?

Shares of MASI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Masimo's stock price today?

One share of MASI stock can currently be purchased for approximately $245.74.

How much money does Masimo make?

Masimo has a market capitalization of $13.58 billion and generates $937.84 million in revenue each year. The medical equipment provider earns $196.22 million in net income (profit) each year or $3.22 on an earnings per share basis.

How many employees does Masimo have?

Masimo employs 2,000 workers across the globe.

When was Masimo founded?

Masimo was founded in 1989.

What is Masimo's official website?

The official website for Masimo is www.masimo.com.

Where are Masimo's headquarters?

Masimo is headquartered at 52 DISCOVERY, IRVINE CA, 92618.

How can I contact Masimo?

Masimo's mailing address is 52 DISCOVERY, IRVINE CA, 92618. The medical equipment provider can be reached via phone at 949-297-7000 or via email at [email protected]


This page was last updated on 4/17/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.